Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT07345741 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

R/R B-NHL
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL)

Interventions

DRUG: AcNK-Sup003 cell injection

Sponsor

Donghua Zhang